Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emitavir phosphate + sofosbuvir for genotype 1 chronic hepatitis C (real-world, multicenter cohort)
ChiCTR2500104620Phase 4Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of yimitasvir and sofosbuvir in hepatitis C virus infection, sponsored by Beijing Ditan Hospital. Primary endpoint: Sustained Virological Response 12 weeks after end of treatment (SVR12). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
yimitasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ChiCTR2500104620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104620.